Acadia PharmaceuticalsACAD
ACAD
About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Employees: 654
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
426% more call options, than puts
Call options by funds: $30.3M | Put options by funds: $5.77M
68% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 38
8% more funds holding
Funds holding: 294 [Q4 2024] → 317 (+23) [Q1 2025]
4.86% more ownership
Funds ownership: 97.91% [Q4 2024] → 102.77% (+4.86%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 102
5% less capital invested
Capital invested by funds: $2.99B [Q4 2024] → $2.85B (-$142M) [Q1 2025]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
7%
downside
Avg. target
$29
25%
upside
High target
$38
61%
upside
13 analyst ratings
10 positive
77%
3 neutral
23%
0 negative
0%
JP Morgan Tessa Romero | 45%upside $34 | Overweight Maintained | 24 Jul 2025 |
Oppenheimer Jay Olson | 7%downside $22 | Perform Maintained | 26 Jun 2025 |
JMP Securities Jason Butler | 57%upside $37 | Market Outperform Reiterated | 26 Jun 2025 |
HC Wainwright & Co. Andrew Fein | 36%upside $32 | Buy Reiterated | 26 Jun 2025 |
Needham Ami Fadia | 28%upside $30 | Buy Reiterated | 26 Jun 2025 |
Financial journalist opinion
Based on 6 articles about ACAD published over the past 30 days
Positive
Zacks Investment Research
9 hours ago
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Seeking Alpha
2 days ago
Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In
ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk catalyst, with a 60–65% probability of success due to improved trial design. We believe ACP-101's market potential is lower than consensus, estimating $400M peak revenue due to late market entry and dosing frequency.
Neutral
Business Wire
1 week ago
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until November 5, 2025. The conference call may a.
Positive
Investors Business Daily
2 weeks ago
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Neutral
Zacks Investment Research
3 weeks ago
KMDA or ACAD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Neutral
Business Wire
3 weeks ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' em.
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strateg.
Neutral
Zacks Investment Research
1 month ago
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' e.
Neutral
Business Wire
1 month ago
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent est.
Charts implemented using Lightweight Charts™